Overweight and Obesity in Dogs and Cats
Pet obesity, Overweight, Excess body weight, Adiposity, Body condition score above ideal (vets use either a 5-point or a 9-point scale - ask which one your clinic uses, because the same pet scores differently on each), Canine obesity, Feline obesity
Overweight means your pet is carrying more body fat than is healthy for them. It is the most common preventable health problem in dogs and cats, and it is easy to miss because it happens slowly and because a chubby pet still looks happy. Carrying extra weight makes joints hurt more, makes moving and breathing harder, and in DOGS specifically it is linked to a shorter life. Extra weight can genuinely come off, and it comes off without injections, supplements or special treatments: measured meals of a proper weight-loss food, chosen and monitored by your veterinarian. Be ready for real work, though. It takes months, and in one veterinary study only about 3 in 5 dogs enrolled in a weight-loss programme finished it - so the plan has to be one your household can actually keep to, and it has to continue after the target weight or the weight comes back. Three rules that matter more than anything else on this page. NEVER give your pet human pain medicine - ibuprofen, naproxen, aspirin, or acetaminophen/paracetamol - because these poison dogs and cats at doses that are ordinary for people. NEVER give one animal's medicine to another animal, and never give a dog's anti-inflammatory to a cat. And NEVER give your pet a human weight-loss product - not semaglutide, tirzepatide or liraglutide 'pens', not orlistat, metformin, thyroid tablets or diet pills - none of them has an approved dose in dogs or cats, and in cats anything that suppresses appetite is dangerous. If you want to change the food, the amount, a supplement or any medicine, call your clinic first and change nothing until you have spoken to them.
What you might notice
- You cannot see a waist when you look down at your pet from above - the outline goes straight, or bulges out, instead of tucking in behind the ribs
- You have to press to feel the ribs, or you cannot feel them at all
- The belly hangs down or swings when your pet walks, and there is a soft fat pad between the back legs. IMPORTANT: a fat belly builds up slowly over months. A belly that gets bigger over days or a couple of weeks, or that feels tight and full of fluid, is NOT fat - see the red flags below and get it checked
- The collar, harness or coat has needed loosening or a bigger size
- Dogs: slower on walks, lags behind, pants more, lies down partway through a walk, or is stiff after getting up
- Cats: stops jumping onto worktops or the windowsill, uses a chair as a step, or sleeps much more than before
- Cats: dandruff, mats or greasy fur on the lower back and around the tail, because they can no longer reach to groom there
- Less interested in play, and gets out of breath or overheats quickly in warm weather
- Any weight-loss plan should be one you agreed with your clinic. If you find yourself changing the food, the portion, a supplement or a medicine on your own, stop and call them first
Standard of care
Nutritional assessment with BCS and MCS at every examination
Approved / guideline-backedWeigh, body-condition-score and muscle-condition-score at every visit; set an explicit target weight and target BCS; individualise the daily energy allowance rather than using a bag-label amount. This is the screening step that closes the diagnosed-versus-true prevalence gap, and it is free. The muscle condition score is not decoration: it is the field that tells you whether this patient should be restricted at all.
2021 AAHA Nutrition and Weight Management Guidelines for Dogs and Cats state that nutritional assessment including a body condition score and muscle condition score 'is a screening evaluation that should ideally be performed at every examination,' with individualised recommendations designed to achieve and maintain an appropriate body weight. Guideline consensus covering both species.
Confirm the patient is a candidate for energy restriction before restricting anything
Approved / guideline-backedEnergy restriction and therapeutic weight-loss diets are NOT for growing puppies and kittens, pregnant or lactating animals, or patients at risk of cachexia - chronic kidney disease, cardiac disease, neoplasia, or any patient with a reduced muscle condition score. A high BCS with a low MCS is not an indication to restrict; it is an indication to investigate. Where a therapeutic diet or drug is involved, check the product's own label limits for species, minimum bodyweight, minimum age, and pregnancy/lactation/breeding before dispensing - several of the products named on this page carry exactly those restrictions (see the drug-therapy step and safety). Also settle the household logistics before starting, because a measured ration is unenforceable where animals share bowls or one cat free-feeds: separate feeding rooms or crates, timed or microchip-activated feeders, no communal free-choice bowl, and a named person responsible for the food. Multi-pet feeding is the commonest practical reason feline plans fail.
Named products: None for this step. The label limits quoted are for two FDA-approved FELINE drugs that are not weight-loss drugs and appear here only because they are named elsewhere on this page: capromorelin (Elura, NADA 141-536) and bexagliflozin (Bexacat, NADA 141-566).
Guideline-directed: the 2021 AAHA Nutrition and Weight Management Guidelines pair body condition score with MUSCLE condition score at every examination precisely because adiposity and lean-mass loss can coexist, and individualise the recommendation to life stage (PMID 34228790). The label limits cited on this page are taken from the FDA-approved labels themselves (Elura, NADA 141-536: 'The safe use of ELURA has not been evaluated in cats younger than 5 months old' and not in 'cats that are pregnant, lactating, or intended for breeding'; Bexacat, NADA 141-566: dosing restricted to 'cats weighing 6.6 lbs (3.0 kg) or greater' and safety 'in breeding, pregnant, and lactating cats has not been evaluated'). No trial evidence is claimed for the multi-pet household advice - it is practical and stated as such.
Controlled energy restriction with a therapeutic weight-management diet - the entire core of treatment
Controlled trial in this speciesA measured, calculated daily ration of a diet formulated for weight loss (so that protein, micronutrients and fibre stay adequate while energy falls), divided into defined meals, with all treats and medication-vehicles counted inside the allowance. Do not simply feed less of the current maintenance food. BOUND THE RATE, because the main hazard of this step is rate-dependent: the attending veterinarian sets the target, and the rate conventionally used in practice is a ceiling of roughly 1-2% of bodyweight per week in dogs and a more conservative roughly 0.5-1% per week in cats. Never go below the energy floor the veterinarian calculates for that specific therapeutic diet, because below it the ration no longer delivers adequate protein and micronutrients. A cat must NEVER be fasted or crash-dieted. If the pet becomes inappetent, vomits or is unwell, the plan is SUSPENDED and the clinic is called - it is not pushed harder. Expect, and plan for, a gradual rise in maintenance energy requirement after target weight is reached - weight regain is the default outcome without a maintenance plan.
Named products: None. This step is dietary. No drug is required and none is approved for it (see the drug-therapy step below).
THE OUTCOME EVIDENCE IS ASYMMETRIC BETWEEN SPECIES AND MUST BE READ THAT WAY. DOGS - clinical-outcome evidence: in 9 client-owned dogs weighing 11-12% above ideal body weight with radiographic hip OA, a 60%-of-maintenance restricted-calorie diet produced 11-18% loss of INITIAL bodyweight and significantly decreased bodyweight, BCS and hindlimb lameness severity (PMID 10754668; non-blinded prospective clinical trial, n=9, first-author affiliation the Iams Co, a pet-food manufacturer). In a randomised but explicitly NON-BLINDED trial of 29 overweight/obese dogs with clinical and radiographic OA, caloric restriction achieved significant weight loss in both arms and improved mobility and ground-reaction-force symmetry at 6 months (PMID 17144822; shares a co-author, Tetrick MA, with the Iams-affiliated trial above). Both load-bearing canine trials are small, non-blinded and pet-food-industry-linked, and that is disclosed here on the same terms as the industry authorship disclosed for dirlotapide below. CATS - body-composition and energy-requirement evidence ONLY: in a randomised veterinary trial of 16 obese cats using DXA, a controlled regimen achieved 23.0 +/- 2.8% bodyweight reduction, with 50.3 +/- 9.4% (males) and 37.0 +/- 8.9% (females) reduction in trunk fat, and identified a 12.9 +/- 3.4% higher energy intake requirement in males for the same rate of loss (PMID 31106916). That study shows cats lose fat when fed less; it does not show that any clinical outcome improves. NO feline trial located demonstrates an improvement in a clinical outcome from weight loss. The feline rationale therefore rests on the bodyweight-to-diabetes association (PMID 27353396) and on avoiding iatrogenic harm, NOT on demonstrated outcome benefit. GUIDELINE - therapeutic weight-loss diets and individualised energy prescriptions per PMID 34228790.
Structured, graded increase in activity - and in dogs specifically, physical therapy alongside the diet
Controlled trial in this speciesFor dogs: a prescribed, progressive exercise or physiotherapy programme added to the diet, scaled to current fitness and to any orthopaedic disease. For cats: environmental and behavioural change rather than exercise prescription - measured meals, food puzzles and foraging feeders, multiple feeding stations, vertical space, and play sessions. Feeding-method change is the feline lever with actual support; activity in cats is reasonable, welfare-positive and unproven, and this page does not claim the evidence rules it out.
DOGS - randomised, non-blinded trial, 29 overweight/obese dogs with OA: both arms received identical dietary restriction; the arm receiving intensive physiotherapy (including transcutaneous electrical nerve stimulation) achieved greater weight reduction and the best mobility and ground-reaction-force symmetry outcomes at 6 months. Authors' conclusion: 'Caloric restriction combined with intensive physical therapy improved mobility and facilitated weight loss in overweight dogs' (PMID 17144822). CATS - THE EVIDENCE IS INSUFFICIENT IN EITHER DIRECTION, and this page previously overstated it. No trial has shown that increasing activity drives weight loss in cats. The one cross-sectional dataset located (n=63, Vietnam) found no association between obesity and exercise frequency, housing, diet type or begging behaviour, while neuter status and ad-libitum feeding WERE associated - but that study was designed as a POMC c.28G>C genotyping study in 63 clinically healthy cats, the husbandry variables were self-reported secondary items with no power calculation, and its 'normal weight' comparison band was BCS 5-6/9, which places overweight cats in the control group and biases every null toward the null (PMID 42288060). Absence of evidence here is not evidence of absence. Feeding-method change is the intervention with actual support.
Treat the comorbidity the weight is driving - and expect the weight loss itself to be analgesic in dogs
Controlled trial in this speciesIn dogs, assess and treat osteoarthritis pain concurrently; weight reduction is not an alternative to analgesia but it measurably reduces the pain burden, so re-assess analgesic need as weight falls. In cats, the primary comorbidity to act on is diabetes risk, and weight management is the principal modifiable lever for it. Analgesia does NOT cross species: a dog's NSAID choice or dose must never be used in a cat, no owner-administered NSAID should be running without the clinic's instruction, and acetaminophen/paracetamol must never be given to a cat at any dose. Do not assume the feline OA-weight relationship mirrors the canine one (see safety).
DOGS - weight reduction alone significantly decreased hindlimb lameness severity in dogs with hip OA (PMID 10754668); health-related quality of life measured with a validated standardised questionnaire in 50 obese client-owned dogs showed, in the 30 that reached target, increased vitality (P<0.001) and decreased emotional disturbance (P<0.001) and pain (P<0.001) scores, with the vitality change positively associated with percentage weight loss (r=0.43, P=0.02) and percentage body-fat loss (r=0.39, P=0.03); anxiety did not change (P=0.09) (PMID 22075257). CATS - DM odds rose with increasing BODYWEIGHT category above 4 kg (P<0.001) among 1,128 DM cases from 193,435 cats in English primary care (PMID 27353396); that study measured bodyweight, not body condition, so frame size is uncontrolled and the association is supportive rather than a clean adiposity effect.
Scheduled recheck weigh-ins with plan revision - the step most often skipped and the one that decides the outcome
Controlled trial in this speciesBook the next weigh-in before the client leaves. Re-measure weight, BCS and MCS; recalculate the allowance against actual loss rather than predicted loss; and change the plan when the pet is not losing, rather than repeating the same instruction. Tell the owner in words that nothing about the plan changes between visits without a phone call - not the food, not the portion, not a supplement, not a medicine. After target weight, energy requirement rises progressively, so the maintenance ration must be re-titrated or the pet will regain.
Guideline-directed (PMID 34228790: serial nutritional assessment and individualised recommendations). Empirically supported by outcome data: in 50 obese dogs enrolled in a weight-loss programme, only 30 reached target, and dogs that failed to complete had lower vitality and higher emotional-disturbance scores at enrolment (P=0.03 for both) - i.e. attrition is the main failure mode and is partly predictable at baseline (PMID 22075257). In cats, energy requirement increased progressively over the 17 weeks of maintenance after weight loss (P<0.05) (PMID 31106916).
Prevention from the first puppy or kitten visit, because the trajectory is set early
Early evidenceSet a measured feeding plan, a treat budget and a weigh-in schedule at the paediatric visits, not at the point where the pet is already obese. In cats especially, discourage ad-libitum feeding from the outset. Note that prevention in a growing animal means an appropriate growth ration, never energy restriction.
In a breeding colony of cats fed ad libitum from weaning, growth curves were modelled on 212 cats and the 9-year outcome was evaluated in the subset of 146 cats that had reached 9 years of age. In those cats, male sex, bodyweight at around 15 weeks of age, and being born during the increasing photoperiod were significantly associated with being overweight at 9 years, whereas maternal factors, birth weight and litter size were not. The authors' own conclusion, quoted in full: 'Thus, the trajectory to obesity is determined early in life in cats, and early intervention appears essential to prevent obesity in pet cats.' Colony study, not a client-owned intervention trial - tier 3.
Drug therapy for weight loss - there is none currently marketed, in either species
No evidence locatedState this plainly to clients who arrive asking for a weight-loss injection or pill. Two anti-obesity veterinary drugs have existed for dogs, and both are gone. Dirlotapide (Slentrol), a microsomal triglyceride transfer protein inhibitor, was marketed from 2007 through 2010; its EU marketing authorisation (EMA, EMEA/V/C/000116) has been withdrawn at the marketing-authorisation holder's request, management was labour-intensive, and gastrointestinal side effects were unacceptable to owners. Mitratapide (Yarvitan) was authorised in the EU by the EMA (EMEA/V/C/000113, first authorised 4 September 2007) with its own recommended treatment schedule, and that authorisation has likewise been withdrawn at the holder's request. In cats, there has never been an approved weight-loss drug at all. No GLP-1 receptor agonist is approved for dogs or cats by any regulator located. As of 12 September 2026 no weight-loss drug is marketed for either species in the US or the EU - a dated negative that must be re-verified against the FDA Green Book / Animal Drugs @ FDA before publication and on a recurring schedule, because this is a fast-moving area. Any product offered for pet weight loss today is either a diet, a supplement with no efficacy evidence in these species, or an unapproved drug. And owners must be told explicitly not to reach for their own prescription: no human weight-loss or diabetes drug has an established dose in dogs or cats (see safety).
Named products: Dirlotapide (Slentrol) - licensed for canine weight reduction, marketed 2007-2010; EU marketing authorisation withdrawn (EMA EMEA/V/C/000116). Mitratapide (Yarvitan) - EU-authorised for dogs by the EMA (EMEA/V/C/000113, 4 September 2007), marketing authorisation withdrawn at the holder's request; adding it to a low-fat high-fibre diet produced no additional weight loss (PMID 24920548). NO weight-loss drug has ever been approved for cats. NO GLP-1 receptor agonist is approved for dogs or cats. Capromorelin (Elura, FDA NADA 141-536, approved 19 October 2020) is FDA-approved for CATS ONLY, for 'management of weight loss in cats with chronic kidney disease' - it is an appetite stimulant and works in the opposite direction; it must never be cross-sold into an obesity context, and its label warns 'Do not use in cats with hypersomatotropism (acromegaly),' states it 'may increase serum glucose for several hours after dosing,' and states its safe use has NOT been evaluated in cats younger than 5 months or in pregnant, lactating or breeding cats. Bexagliflozin (Bexacat, FDA NADA 141-566) and velagliflozin (Senvelgo, FDA NADA 141-568) are FDA-approved for CATS ONLY and for DIABETES ONLY, not for weight loss, and both carry a boxed warning for diabetic and euglycaemic ketoacidosis. Exenatide extended-release is a HUMAN drug with no veterinary approval in any jurisdiction located.
A 2025 AJVR review states verbatim that dirlotapide 'was available from 2007 through 2010,' that 'managing dogs on dirlotapide was labor intensive, and gastrointestinal side effects were unacceptable to dog owners,' and argues only speculatively that owner tolerance may now have changed - it is a proposal to revisit the molecule, not evidence of a current product (PMID 40882685). The original dirlotapide product literature describes the mechanism, dose-titration burden and the peptide-YY-mediated appetite reduction (PMID 17567510, PMID 17567509) - note both are manufacturer-authored. For mitratapide, PMID 19544001 studied 'the recommended treatment schedule of mitratapide (Yarvitan)' in obese Beagles (DXA-confirmed fat loss, mean 41.6% of baseline body fat mass), and a 36-dog randomised trial found that adding mitratapide to a low-fat high-fibre diet 'does not seem to offer any further useful effect in the loss of weight during the treatment of canine obesity' (PMID 24920548) - which supports this protocol's diet-is-the-core position directly. Current authorisation status for both products taken from the EMA product pages. Tier 5: no currently available evidence-based pharmacotherapy.
What the outcome evidence says the stakes are - use this to motivate, in dogs; be more careful in cats
Controlled trial in this speciesIn dogs the survival argument is strong and can be made honestly. In cats it is genuinely weaker and partly contradictory, and the site must say so rather than importing the canine message.
DOGS - 25% diet restriction from 8 weeks of age until death in 48 paired Labrador Retrievers significantly lengthened median life span and generally delayed onset of clinical signs of chronic disease (PMID 11991408), and in the same cohort severity of radiographic shoulder OA was significantly lower in diet-restricted dogs at 6 and 8 years (PMID 18199063). In 50,787 middle-aged neutered client-owned dogs across ~900 North American hospitals, instantaneous risk of death was greater for overweight dogs in all 12 breeds studied, with hazard ratios from 1.35 (99.79% CI 1.05-1.73, German Shepherd Dog) to 2.86 (99.79% CI 2.14-3.83, Yorkshire Terrier); median life span was shorter in overweight dogs in every breed, the largest gap being Yorkshire Terriers (overweight 13.7 y vs normal 16.2 y) (PMID 30548336). Banfield life-expectancy tables on 13,292,929 dogs: obese dogs (BCS 5/5) 11.71 y (11.66-11.77) versus overweight 13.14 y (13.12-13.16) and ideal 13.18 y (13.16-13.19) (PMID 36896289). CATS - the same Banfield analysis of 2,390,078 cats found life expectancy for BCS 4/5 cats [13.67 y (13.62-13.71)] was significantly HIGHER than for BCS 5/5 [12.56 y (12.45-12.66)] and also higher than for ideal BCS 3/5 [12.18 y (12.14-12.21)]. That is not a typographical error and it must not be omitted: in cats, frank obesity is associated with shorter life expectancy, but modest overweight in this dataset was not.
2021 AAHA Nutrition and Weight Management Guidelines for Dogs and Cats — American Animal Hospital Association (AAHA)
How it is diagnosed
- Weigh on a calibrated scale at every visit and plot the trend - a single weight is not data, a trend is. Record bodyweight in the record in a charted field, not free text.
- Assign a body condition score AND a muscle condition score at every examination, as the 2021 AAHA Nutrition and Weight Management Guidelines specify. Use one scale consistently (9-point or 5-point) and record which. MCS matters independently and it is also a STOP rule: a pet can be overweight and sarcopenic at the same time, and a patient with reduced muscle condition should not be energy-restricted on the strength of a high BCS alone.
- Estimate ideal bodyweight and set an explicit numeric target weight and target BCS, then calculate a daily energy allowance from it. Remember that neutered male cats need more energy than neutered females for the same rate of loss (PMID 31106916), so a single per-kg formula will mis-dose one sex.
- Take a full diet history: every food, every treat, dental chews, food used to give medication, table scraps, food stolen or hunted, other people in the household who feed, and the actual measuring method (a scoop is a known risk factor in cats - PMID 31482097). Ask whether feeding is measured or ad libitum, and ask specifically how many other animals eat in the house and whether bowls are shared or free-fed.
- Exclude and quantify endocrine mimics before calling it simple obesity. DOGS: total T4 and TSH for hypothyroidism, plus screening for hyperadrenocorticism if clinical signs are present, and a glucocorticoid exposure history. Calibrate the thyroid suspicion: in UK primary care the annual prevalence of diagnosed hypothyroidism was only 0.23% (95% CI 0.22-0.24), and although the Standard Doberman Pinscher OR was 17.02 (95% CI 12.8-22.64) vs crossbreds, that is an odds ratio for carrying a DIAGNOSIS, not for disease - the same model found bodyweight above the breed-sex mean and rising adult bodyweight independently raised the odds of carrying the diagnosis, i.e. heavy dogs get tested more. Test on clinical suspicion, not on adiposity alone (O'Neill DG et al. Canine Med Genet 2022;9(1):11. PMID 36217196. DOI 10.1186/s40575-022-00123-8). CATS: untreated hyperthyroidism causes weight LOSS, so unexplained weight gain is rarely primary hyperthyroidism - but DO check total T4 in any cat previously treated with radioiodine or methimazole, because iatrogenic hypothyroidism causes weight gain and lethargy and worsens renal prognosis in azotaemic cats. Assess glucose/fructosamine, and consider IGF-1 for hypersomatotropism (acromegaly) in a cat gaining weight with insulin resistance or organomegaly.
- Screen the species-appropriate comorbidity. DOGS: structured orthopaedic and OA pain assessment, since weight reduction alone significantly improves lameness (PMID 10754668). CATS: diabetes risk - DM odds rose with increasing BODYWEIGHT category above 4 kg (P<0.001; 1,128 cases among 193,435 cats in English primary care, PMID 27353396). That study categorised cats by bodyweight, not by body condition score, so frame size is uncontrolled and insured cats carried OR 2.0 (a care-seeking marker, not biology) - the association is supportive but is not a clean adiposity effect. Screen feline degenerative joint disease on its own merits rather than assuming weight causes it.
- Decide, explicitly, whether this patient should be energy-restricted AT ALL. Do not put a growing puppy or kitten, a pregnant or lactating animal, or a patient at risk of cachexia (chronic kidney disease, cardiac disease, neoplasia, any reduced muscle condition score) on a weight-reduction ration. In those patients the goal is appropriate growth or weight stabilisation with adequate protein, managed by the attending veterinarian, not restriction.
- Assess owner capability, household constraints and readiness honestly, and plan the conversation. The AAHA guideline devotes explicit attention to this because owners may read dietary advice as a judgment of their care, or of their own weight - and a plan the household cannot execute is not a plan.
Where a biologic fits
Our own product, graded by the same rule
There is no mesenchymal stem cell, exosome or peptide product with any published efficacy evidence for weight loss in dogs or cats, and PetSmartMeds does not offer one for this condition: overweight and obesity are treated with a measured, calculated ration of a therapeutic weight-management diet and scheduled recheck weigh-ins, which is effective in dogs, inexpensive, and carries none of the risk of an unapproved injectable - and in cats, an appetite-suppressing product is actively dangerous, because a cat that stops eating can develop fatal hepatic lipidosis.
What exists
Nothing that supports a biologic for weight loss in either species. Taking each category in turn, with the species labelled: (1) MESENCHYMAL STEM CELLS - the entire body of controlled canine MSC evidence is for OSTEOARTHRITIS, not weight: a randomised, double-blinded, placebo-controlled trial of autologous adipose-derived cells in canine coxofemoral OA (Black et al. 2007, PMID 18183546, DOG); a multicentric randomised placebo-controlled trial of xenogeneic EQUINE umbilical-cord MSCs in 80 client-owned dogs with elbow or hip OA, best results at 8 weeks (Punzon et al. 2022, PMID 36198051, DOG); and DogStem, which uses EQUINE umbilical-cord MSCs in DOGS and is authorised by the EUROPEAN MEDICINES AGENCY (EMEA/V/C/005829) - an EU authorisation only, not an FDA approval - whose pivotal field trial reported 51% of treated dogs versus 5% of placebo dogs meeting the primary force-plate gait endpoint at 8 weeks. No MSC study of any kind for obesity, adiposity or bodyweight as an indication in dogs or cats was located. (2) EXOSOMES / EXTRACELLULAR VESICLES - there is no published in-vivo clinical efficacy evidence for exosome or EV products in dogs or cats for ANY indication, and for obesity specifically the only place EVs appear in the canine literature is as a BIOMARKER, not a treatment: in 32 neutered female dogs (21 obese, 11 controls), obese bitches WITH hypertriglyceridaemia showed increased serum small-EV concentration and increased miR-132 and miR-26b expression, with no change in obese bitches that had a normal biochemical profile and no change in miR-155 (da Silva Nunes et al. 2022, PMID 36180561, DOG - observational, descriptive, no intervention). Feline adipose-MSC secretome work is in-vitro shotgun proteomics under different culture conditions (Lara et al. 2023, PMID 36931338, CAT - cell culture only). (3) PEPTIDES - AOD-9604: no dog or cat records located; its human obesity programme did not produce an approved weight-loss drug. 5-Amino-1MQ: mouse diet-induced-obesity and in-vitro adipocyte work only, no dog or cat records, and it is a small-molecule quinolinium rather than a peptide. SLU-PP-332: mouse only, no dog or cat records, also a small molecule. MOTS-c: no controlled target-species study. Tesamorelin, CJC-1295, sermorelin, ipamorelin, hexarelin, GHRP-6: no canine or feline clinical efficacy studies located, and several are on an active FDA list of bulk substances that may present significant safety risks. BPC-157 and TB-500: essentially nothing in companion animals - the only canine BPC-157 record is a beagle pharmacokinetics study (PMID 36588717), and TB-500 is FEI-banned. (4) THE ONE NEAR-MISS, STATED HONESTLY - exenatide, a GLP-1 receptor agonist, is a HUMAN drug with genuine randomised evidence in CATS, but for DIABETES, not obesity, and it did not cause weight loss: in 30 newly diagnosed diabetic cats, exenatide extended-release added to insulin glargine and a low-carbohydrate diet did not meet its primary endpoints (remission 40% vs 20%, P=0.427); bodyweight INCREASED significantly in the placebo group and did not in the exenatide arm, i.e. the drug prevented insulin-associated weight GAIN rather than producing weight loss; and in the treated arm 60% had decreased appetite and 53% vomited (PMID 26700409). A later 2-year trial in 22 cats in recent remission found no difference in remission duration (placebo 669 vs exenatide-ER 662 days, P=0.9) (PMID 40105430). The investigational OKV-119 exenatide implant produced reduced caloric intake and weight loss in 4 of 5 purpose-bred cats with at least 5% bodyweight reduction maintained to day 112 (PMID 38762728) - n=5, prototype device, purpose-bred cats, no approval anywhere. None of that is a PetSmartMeds MSC, exosome or peptide product, and none of it is approved for weight loss in any species by any regulator.
What has not been shown
No controlled clinical trial of any mesenchymal stem cell product, any exosome or extracellular-vesicle product, or any catalogue peptide for weight loss, adiposity reduction or metabolic improvement in dogs or cats has been located. No animal cell- or tissue-based product is FDA-approved: FDA states verbatim that 'Currently, no ACTPs are FDA-approved' and that 'It is illegal to market an unapproved ACTP because it hasn't gone through the required FDA pre-market review and approval process' - and FDA CVM has enforced against conditioned media (the upstream material for exosome preparations) as an unapproved new animal drug. DogStem's authorisation is an EMA (EU) authorisation for dogs and confers nothing in the US. There is no approved GLP-1 receptor agonist for dogs or cats; tirzepatide and retatrutide are named in FDA Warning Letter 721806 (Gram Peptides, 31 March 2026) as unapproved new drugs, with the 'not intended for veterinary use' disclaimer expressly rejected. As of 12 September 2026 there is no weight-loss drug marketed for dogs or cats in the US or the EU. And these products are NOT immune-privileged: Punzon et al. found that BOTH equine and canine MSCs RAISED antibody titres in dogs (Front Vet Sci 2023;10:1098029, PMID 37266387) - safety was nonetheless acceptable, but 'immune-privileged', 'immune-invisible' and 'zero-flare' are not defensible claims and must never appear.
Sources
- FDA: no animal cell- and tissue-based product is approved (verbatim, direct fetch) — US Food and Drug Administration. FDA's Role in Veterinary Regenerative Medicine. 'Currently, no ACTPs are FDA-approved.' / 'It is illegal to market an unapproved ACTP because it hasn't gone through the required FDA pre-market review and approval process.' https://www.fda.gov/animal-veterinary/cell-and-tissue-products-a
- DOG - the only EV finding in canine obesity is a biomarker, not a therapy — da Silva Nunes PC, Mazzarella R, da Silveira JC, Dellova DCAL. Evaluation of circulating extracellular vesicles and miRNA in neutered and obese female dogs. Sci Rep 2022;12(1):16439. PMID 36180561. DOI 10.1038/s41598-022-20523-x https://doi.org/10.1038/s41598-022-20523-x
- CAT - feline adipose-MSC secretome work is in-vitro proteomics only — Lara ML, Carvalho MG, de Souza FF, et al. Influence of culture conditions on the secretome of mesenchymal stem cells derived from feline adipose tissue: Proteomics approach. Biochimie 2023;211:78-86. PMID 36931338. DOI 10.1016/j.biochi.2023.03.004 https://doi.org/10.1016/j.biochi.2023.03.004
- CAT - the GLP-1 evidence is for diabetes, missed its primary endpoints, prevented weight GAIN rather than causing loss, and caused inappetence and vomiting — Riederer A, Zini E, Salesov E, Fracassi F, Padrutt I, Macha K, Stockle TM, Lutz TA, Reusch CE. Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus. J Vet Intern Med 2016;30(1):92-100. PMID 26700409. DOI 10.1111/jvim.13817 https://doi.org/10.1111/jvim.13817
- CAT - the negative 2-year exenatide-ER trial that a marketer would bury — Gilor C, Fleeman LM, Hulsebosch SE, et al. J Vet Intern Med 2025;39(2):e70069. PMID 40105430. DOI 10.1111/jvim.70069. 'There was no difference in remission duration between treatments (placebo 669 [121-721] vs exenatide-ER 662 [28-735] days, p = 0.9).' https://doi.org/10.1111/jvim.70069
- CAT - investigational exenatide implant: real weight loss, n=5, purpose-bred, no approval — Klotsman M, Anderson WH, Gilor C. BMC Vet Res 2024;20(1):211. PMID 38762728. DOI 10.1186/s12917-024-04051-6 https://doi.org/10.1186/s12917-024-04051-6
- DOG - MSCs are NOT immune-privileged: both equine and canine MSCs raised antibody titres in dogs — Punzon E, et al. Front Vet Sci 2023;10:1098029. PMID 37266387. https://pubmed.ncbi.nlm.nih.gov/37266387/
- DOG - the genuine canine MSC evidence, and it is for osteoarthritis, not weight; DogStem is an EMA (EU) authorisation, not an FDA approval — Punzon E, et al. J Am Vet Med Assoc 2022. PMID 36198051. DOI 10.2460/javma.22.06.0237 | Black LL, et al. Vet Ther 2007. PMID 18183546 | European Medicines Agency, DogStem (equine umbilical cord-derived mesenchymal stem cells) for DOGS, EMEA/V/C/005829, status Authorised in the EU - pivotal field trial: 51% of DogStem-treated dogs vs 5% of placebo-treated dogs met the primary force-plate endpoint at 8 weeks. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/dogstem
- DOG - the only canine BPC-157 record is beagle pharmacokinetics, not efficacy — He L, et al. Front Pharmacol 2022;13:1026182. PMID 36588717. DOI 10.3389/fphar.2022.1026182 https://doi.org/10.3389/fphar.2022.1026182
Tracking response
How you know whether it is working
Serial bodyweight on a calibrated scale, plus body condition score (9-point or 5-point, used consistently) and muscle condition score, recorded at every examination - with percentage of starting bodyweight lost as the primary tracked outcome, an explicit numeric target weight, and the weekly rate of loss checked against the agreed ceiling rather than only the total. For dogs with concurrent osteoarthritis, a validated owner-completed health-related quality of life instrument can be run alongside, since HRQOL is measurably responsive to weight loss in obese dogs (vitality, emotional disturbance and pain scores all changed significantly, P<0.001, in dogs reaching target). For cats, food intake is monitored as a safety parameter, not just an adherence parameter.
Cline MG, Burns KM, Coe JB, Downing R, Durzi T, Murphy M, Parker V. 2021 AAHA Nutrition and Weight Management Guidelines for Dogs and Cats. J Am Anim Hosp Assoc 2021;57(4):153-178. PMID 34228790. DOI 10.5326/JAAHA-MS-7232 - 'A nutritional assessment, including a body condition score and muscle condition score, is a screening evaluation that should ideally be performed at every examination.' | For the canine HRQOL instrument: German AJ, Holden SL, Wiseman-Orr ML, Reid J, Nolan AM, Biourge V, Morris PJ, Scott EM. Quality of life is reduced in obese dogs but improves after successful weight loss. Vet J 2011;192(3):428-34. PMID 22075257. DOI 10.1016/j.tvjl.2011.09.015 | For post-loss energy re-titration in cats: Vasconcellos RS, et al. J Anim Physiol Anim Nutr 2019;103(5):1546-1555. PMID 31106916.
Suggested cadence: Baseline at enrolment, then a recheck weigh-in every 2 to 4 weeks during active weight loss, with the daily energy allowance recalculated against ACTUAL rather than predicted loss at each visit, and the rate of loss compared with the agreed ceiling in both directions - too slow means revise the plan, too fast means slow it down, especially in cats. Once target weight and target BCS are reached, weigh monthly for 3 months and then at least every 3 months for life, because energy requirement rises progressively after weight loss and the default outcome without a maintenance plan is regain. Cats additionally need a food-intake check at every contact, because falling intake is the warning sign that matters most in that species, and any cat that is off food for more than about 24 hours is an unscheduled same-day contact rather than a note for the next visit. Attrition, not biology, is the main failure mode - in one cohort of 50 obese dogs only 30 reached target - so the next appointment should be booked before the client leaves.
Questions you can answer at home
- Standing over your pet and looking down, can you see a waist behind the ribs - yes, only just, or no?
- Running your flat hand along the side of the chest with light pressure, can you feel the individual ribs easily, only with firm pressure, or not at all?
- What did the scale say this week, and is that more, less or the same as last time?
- In the last week, did anyone give food, treats, chews or table scraps that were not part of the measured plan - and roughly how much? Include visitors, children and anyone who feeds outside the house.
- Has anything about the plan changed since we set it - the food, the amount, a supplement, a medicine, or a dose - and did you speak to us before changing it? If something needs to change, call us first.
- Cats only, and this one matters most: has your cat eaten its full measured portion every day this week? If your cat has left food or eaten noticeably less for more than a day, contact your veterinary clinic rather than waiting.
- Cats only, for a male cat: has he been going to the litter box more often, straining, crying in the box, or producing little or no urine? That is a same-hour emergency, not a question for the next visit.
- Has your pet's belly got bigger over the last few days or weeks, or does it feel tight rather than soft? A belly that grows quickly is not fat.
- Is your pet drinking or urinating more than usual, or losing weight faster than we planned?
- Do other animals in the house share bowls or have food left out, and could your pet be eating theirs?
- Dogs only: on a normal walk this week, did your dog keep up the whole way, lag behind, or need to stop and rest?
- Compared with a month ago, is your pet more willing or less willing to play, jump up, or use the stairs?
Last reviewed: 2026-09-12 · Every claim on this page carries a citation you can check. If one does not hold up, tell us and we will correct it. science@azzamedical.com
Build a profile for your pet
Tell us what you are dealing with and the site will show you only what applies.